Sie befinden sich hier

Inhalt

Publikationen

2019

Pazan F, Weiss C, Wehling M. The FORTA (Fit fOR The Aged) List 2018: Third Version of a Validated Clinical Tool for Improved Drug Treatment in Older People. Drugs Aging. 2019 Apr 2. [Epub ahead of print]

Pazan F, Kather J, Wehling M. A systematic review and novel classification of listing tools to improve medication in older people. Eur J Clin Pharmacol. 2019 Jan 26. [Epub ahead of print]

Pazan F, Burkhardt H, Frohnhofen H, et al. Higher Fit-fOR-The-Aged (FORTA) Scores Comprising Medication Errors are Associated with Impaired Cognitive and Physical Function Tests in the VALFORTA Trial. Drugs Aging. 2019;36:269-277.

2018

Pazan F, Burkhardt H, Frohnhofen H, Weiss C, Throm C, Kuhn-Thiel A, Wehling M. Changes in prescription patterns in older hospitalized patients: the impact of FORTA on disease-related over- and under-treatments. Eur J Clin Pharmacol 74, 339-47, 2018

Pazan F, Weiss C, Wehling M. The EURO-FORTA (Fit fOR The Aged) list: international consensus validation of a clinical tool for improved drug treatment in older people. Drugs Aging 35, 61-71,  2018

Wehling, M. Rapid actions of aldosterone revisited: receptors in the limelight. J Steroid Biochem Mol Biol 176, 94-8, 2018

2017

Cimminiello C, Prandoni P, Agnelli G, Di Minno G, Polo Friz H, Scaglione F, Boracchi P, Marano G, Harenberg J. Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis. Intern Emerg Med 12, 1291-305, 2017

Pazan F, Wehling M. The FORTA (Fit fOR The Aged) app as a clinical tool to optimize complex medications in older people. J Am Med Dir Assoc 18, 893, 2017

Wehling M, Collins R, Gil VM, Hanon O, Hardt R, Hoffmeister M, Monteiro P, Quinn TJ, Ropers D, Sergi G, Verheugt FWA. Appropriateness of oral anticoagulants for the long-term treatment of atrial fibrillation in older people: results of an evidence-based review and international consensus validation process (OAC-FORTA 2016). Drugs Aging 34, 499-507, 2017

Wehling M. Clinical data were available. Dtsch Arztebl Int 114, 194, 2017

Wehling M. Drug therapy for older people: choosing wisely. Z Gerontol Geriatr 50, 685-8 [Arzneitherapie des älteren Menschen - choosing wisely.] [Article in German]

Wehling M. Pharmakologie, Pharmakokinetik und Pharmakodynamik des geriatrischen Patienten. Geriatr Onkol 2017, doi:10.1007/978-3-662-49083-9_2-1

Wehling M. Polypharmazie bei Menschen mit Diabetes. Diabetologe 13, 72-3, 2017

Wehling M. Rapid actions of steroid hormones: clinical implications with particular reference to hypoxia and ischemia. Adaptive Medicine 9, 109-13, 2017

Weitz JI, Harenberg J. New developments in anticoagulants: past, present and future. Thromb Haemost 117, 1283-8, 2017

Wendler A, Wehling M. Translatability score revisited: differentiation for distinct areas. J Transl Med 15, 226, 2017

2016

Bahrmann P, Harms F, Schambeck CM, Wehling M, Flohr J. Neue orale Antikoagulanzien zur Prophylaxe von Schlaganfällen. Ergebnis einer Expertenkonferenz zum praktischen Einsatz bei geriatrischen Patienten. Z Gerontol Geriatr 49, 216-26, 2016

Bahrmann P, Harms F, Schambeck CM, Wehling M, Flohr J. Neue orale Antikoagulanzien zur Prophylaxe von Schlaganfällen. Ergebnis einer Expertenkonferenz zum praktischen Einsatz bei geriatrischen Patienten. Z Gerontol Geriatr 49, 460-1, 2016

Buch - Wehling M, Burkhardt H. (Hrsg.) Arzneitherapie für Ältere. Springer-Verlag Berlin Heidelberg 4. Auflage 2016 [ISBN-13: 978-3-662-48126-4]

Buchbeitrag - Burkhardt H, Wehling M. Grundlegende Aspekte der Arzneimitteltherapie bei älteren Patienten. In: Alterstraumatologie, Herausgeber: Ruchholtz S, Bücking B, Schulz R-J, Georg Thieme Verlag KG Stuttgart, pp 94-102, 2016 [ISBN-13: 978-3-13-177191-9] [Article in German]

Harenberg J, Du S, Wehling M, Zolfaghari , Weiss C, Krämer R, Walenga J. Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study. Clin Chem Lab 54, 275-83, 2016

Pazan F, Weiss C, Wehling M The FORTA (Fit fOR The Aged) list 2015: update of a validated clinical tool for improved pharmacotherapy in the elderly. Drugs Aging 33, 447-449, 2016

Wehling M, Ashton C, Ekpo E, Gwynn S, Laville M, Olsson K, Spring M. Filling the gap – improving awareness and practice in hyponatraemia and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in the older patient: a European consensus review. Drug Res (Stuttg) 67, 5-12, 2016

Wehling M, Burkhardt H, Kuhn-Thiel A, Pazan F, Throm C, Weiss C, Frohnhofen H. VALFORTA: a randomized trial to validate the FORTA (Fit fOR The Aged) classification. Age Ageing 45, 262-7, 2016

Wehling M. Drugs, older people and doctors; well-being or suffering? A simple list helps to avoid harm and to gain benefits. British Geriatrics Society 01/08/2016. Discussion Age & Ageing Paper VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification. Age Ageing 45, 262-7, 2016.

Blog: https://britishgeriatricssociety.wordpress.com/2016/08/01/drugs-older-people-and-doctors-well-being-or-suffering-a-simple-list-helps-to-avoid-harm-and-to-gain-benefits/

Wehling M. How to use the FORTA (“Fit fOR The Aged”) list to improve pharmacotherapy in the elderly. Drug Res (Stuttg) 66, 57-62, 2016

Wehling M. Older people, a plethora of drugs, and drug list approaches: useful, efficacious, or a waste of time? J Am Med Dir Assoc 17, 1073-5, 2016

Wehling M. Translational science of RRSH (Rapid Responses to Steroid Hormones) on stage: Impressions from the 1st Asian, 9th International RRSH meeting in Taipei, Taiwan. Steroids 111, 1-2, 2016

2015

Bahrmann P, Wehling M, Ropers D, Flohr J, Leischker A, Röther J. Optimal stroke prevention in the geriatric patient with atrial fibrillation: position paper of an interdisciplinary expert panel. Drug Res (Stuttg) 65, 505-14, 2015

Buch - Wehling, M. (ed.) Principles of Translational Science in Medicine - From Bench to Bedside. 2. Edition, Academic Press, Waltham, USA, 2015 [ISBN-13: 978-0-12-800721-1]

Burkhardt H, Wehling M. Non-opioid pain medication in the elderly. Schmerz 29, 371-9, 2015

Du S, Krämer S, Giese C, Weiss C, Wehling M, Krämer R, Harenberg J. Chromogenic assays for measurement of rivaroxaban from EDTA anticoagulated plasma samples. Thromb Haemost 113, 1149-51, 2015

Du S, Weiss C, Giese C, Krämer S, Wehling M, Krämer R, Harenberg J. Determination of dabigatran in plasma, serum, and urine samples: comparison of six methods. Clin Chem Lab Med 53, 1237-47, 2015
Harenberg J, Du S, Krämer S, Krämer R, Wehling M, Weiss C. Measurement of non-vitamin K antagonist oral anticoagulants in patient plasma using Heptest-STAT coagulation method. Ther Drug Monit 37, 375-80, 2015

Harenberg J, Du S, Krämer S, Weiss C, Krämer R, Wehling M. Patients' serum and urine as easily accessible samples for the measurement of non-vitamin K antagonist oral anticoagulants. Semin Thromb Hemost 41, 228-236, 2015

Harenberg J, Hentschel VA, Du S, Zolfaghari S, Krämer R, Weiss C, Krämer BK, Wehling M. Anticoagulation in patients with impaired renal function and with haemodialysis. Anticoagulant effects, efficacy, safety, therapeutic options. Hamostaseologie 35, 77-83, 2015

Krejczy M, Harenberg J, Wehling J, Obermann K, Lip GY. Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany. BioMed Res Int 2015; 2015:876923

Mueller S, Wilke T, Groth A, Fuchs A, Seitz L, Kienhoefer J, Maywald U, Lundershausen R, Wehling M. Factors associated with the risk of diabetes-related events: a retrospective analysis. Value Health 18, A600-1, 2015

Oelke M, Becher K, Castro-Diaz D, Chartier-Kastler E, Kirby M, Wagg A, Wehling M. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014) Age Ageing 44, 745-55, 2015

Wehling M, Throm C. Polypharmazie im Alter – klug entscheiden mit dem FORTA-Prinzip. Dtsch Med Wochenschr 140, 1378-82, 2015

Wehling M. Diabetologie grenzenlos – Besonderheiten der Polypharmakotherapie des alten Patienten (Interview). AdipositasSpektrum 11(2), 6, 2015

Wilke T, Mueller S, Groth A, Fuchs A, Seitz L, Kienhöfer J, Maywald U, Lundershausen R, Wehling M. Treatment-dependent and treatment-independent risk factors associated with the risk of diabetes-related events: a retrospective analysis based on 229,042 patients with type 2 diabetes mellitus. Cardiovasc Diabetol 14, 14, 2015

Wilke T, Wehling M, Amann S, Bauersachs RM, Böttger B. Niereninsuffizienz bei Patienten mit einem thromboembolischen Ereignis: Prävalenz und klinische Implikationen. Dtsch Med Wochenschr 140, e166-74, 2015

Zolfaghari S, Harenberg J, Frölich L, Weiss C, Wehling M, Wild P, Prochaska J, Beyer-Westendorf J, Koscielny J, Lip GY. Development of recommendations to continue anticoagulation with one of the two types of oral anticoagulants based on the identification of patients’ preference. Semin Thromb Hemost 41, 166-177, 2015

2014

Bahrmann P, Wehling M, Ropers D, Flohr J, Leischker A, Röther J. Optimale Schlaganfallprävention bei geriatrischen Patienten mit Vorhofflimmern. Konsensbericht eines Interdisziplinären Expertengremiums. MMW Fortschr Med 156 Suppl.3, 84-8, 2014

Böttger B, Wehling M, Bauersachs RM, Amann S, Schuchert A, Reinhold C, Kümpers P, Wilke T. Prevalence of renal insufficiency in hospitalised patients with venous thromboembolic events: A retrospective analysis based on 6,725 VTE patients. Thromb Res. 134, 1014-9, 2014

Böttger B, Wehling M, Bauersachs RM, Amann S, Wilke T. Initial anticoagulation therapy in patients with venous thromboembolism and impaired renal function: results of an observational study. J Pub Health 22, 89-100, 2014

Harenberg J, Krämer S, Du S, Zolfaghari S, Schulze A, Krämer R, Weiss C, Wehling M, Lip GY. Measurement of rivaroxaban and apixaban in serum samples of patients. Eur J Clin Invest 44, 743-52, 2014

Krejczy M, Harenberg J, Marx S, Obermann K, Frölich L, Wehling M. Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries. J Thromb Thrombolysis 37, 507-23, 2014

Kuhn-Thiel AM, Burkhardt H, Wehling M. Morbus diureticus in the elderly (MDE)-inappropriate application of diuretics. Four case reports. J Aging Sci 2, 3, 2014

Kuhn-Thiel AM, Weiß C, Wehling M; The FORTA authors/expert panel members. Consensus validation of the FORTA (Fit fOR The Aged) list: a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging 31, 131-40, 2014

Michalek C, Wehling M, Schlitzer J, Frohnhofen H. Effects of "Fit fOR The Aged" (FORTA) on pharmacotherapy and clinical endpoints-a pilot randomized controlled study. Eur J Clin Pharmacol. 70, 1261-7, 2014

Wehling M. Editorial: The history of RRSH meetings (Rapid responses to steroid hormones). Steroids 81, 2-3, 2014

Wehling M. L-Arginin und kardiovaskuläre Effekte: neuere Daten zur Gefäßprotektion. Nieren- und Hochdruckkrankheiten 43, 481-8, 2014

Wehling M. Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects. Eur J Clin Pharmacol 70, 1159-1172, 2014

Zolfaghari S, Harenberg J, Froelich L, Wehling M, Weiss C. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy. Semin Thromb Hemost 40, 121-8, 2014

Zolfaghari S, Harenberg J, Wehling M, Frölich L, Weiss C. Entwicklung eines Fragebogens zur Identifikation der Präferenz von Patienten für ein konventionelles oder ein direktes orales Antikoagulanz. MMW Fortschr Med 156, 107-14, 2014

2013

Becher K, Oelke M, Grass-Kapanke B, Flohr J, Mueller EA, Papenkordt U, Schulte-Frei B, Steinwachs KC, Süss S, Wehling M. Improving the health care of geriatric patients: management of urinary incontinence: a position paper. Z Gerontol Geriatr 46, 456-64, 2013

Buch - Wehling M, Burkhardt H (Hrsg.) Arzneitherapie für Ältere. Springer-Verlag Berlin Heidelberg 3. Auflage 2013 [ISBN-13: 978-3-642-34872-3]

Buch - Wehling M. (ed.) Drug Therapy for the Elderly. Springer-Verlag Wien 2013 [ISBN-13: 978-3-7091-0911-3]

Buchbeitrag - Burkhardt H, Wehling M. Pharmakotherapie – Grundlagen der Arzneimitteltherapie bei älteren Patienten. In: Willkomm, M. (Hrsg.) Praktische Geriatrie. Georg Thieme Verlag Stuttgart, 2013, S. 89-96 [ISBN-13: 978-3-13-169781-3]

Wehling M. Editorial. Drug Res (Stuttg) 63, 1, 2013

Wehling M. Morbus diureticus in the elderly: epidemic overuse of a widely applied group of drugs. J Am Med Dir Assoc 14, 437-42, 2013

Wehling M. Paracetamol. Wirksam und sicher bis ins hohe Alter. Schmerz 27, 20-5, 2013

Wehling M. Warum ist die Verschwendungsmedizin gefährlich für Patienten? Monitor Versorgungsforschung 6, 37-40, 2013

Wendler A, Wehling M. PGRMC2, a yet uncharacterized protein with potential as tumor suppressor, migration inhibitor, and regulator of cytochrome P450 enzyme activity. Steroids 78, 555-558, 2013

2012

Albrecht C, Huck V, Wehling M, Wendler A. In vitro inhibition of SKOV-3 cell migration as a distinctive feature of progesterone receptor membrane component type 2 versus type 1. Steroids 77, 1543-1550, 2012

Buchbeitrag - Schmidt-Graf, F., Wehling, M. Akute Intoxikationen. In: Brandt, T., Diener, H.C., Gerloff, C. (Hrsg.) Therapie und Verlauf neurologischer Erkrankungen. 6. Auflage, Kohlhammer Stuttgart 2012, S. 773-84 [ISBN-13: 978-3-17-021674-7]

Harenberg J, Marx S, Dahl OE, Marder VJ, Schulze A, Wehling M, Weiss C. Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery. Thromb Haemost 108, 903-12, 2012

Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network metaanalysis. Int Angiol 31, 330-9, 2012

Harenberg J, Marx S, Wehling M, Krejczy M. New anticoagulants - promising and failed developments. Br J Pharmacol 165, 363-72, 2012

Harenberg J, Marx S, Wehling M. Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: What's next? Thromb Haemost 108, 407-409, 2012

Labeit AM, Klotsche J, Pieper L, Pittrow D, Einsle F, Stalla GK, Lehnert H, Silber S, Zeiher AM, März W, Wehling M, Wittchen HU. Changes in the prevalence, treatment and control of hypertension in Germany? A clinical-epidemiological study of 50.000 primary care patients. PLoS One 7, e52229, 2012

Leistner DM, Klotsche J, Pieper L, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM; DETECT Study Group. Circulating troponin as measured by a sensitive assay for cardiovascular risk assessment in primary prevention. Clin Chem 58, 200-8, 2012 (as collaborator)

Schneider HJ, Klotsche J, Friedrich N, Schipf S, Völzke H, Silber S, März W, Nauck M, Pittrow D, Wehling M, Sievers C, Lehnert H, Stalla GK, Wittchen HU, Wallaschofski H. Risk factors associated with the metabolic syndrome in abdominal obesity. Clin Obes 2, 142-9, 2012

Wehling M, Kuhn-Thiel A. FORTA – Arzneimittelklassifikationssystem für ältere Patienten. Dtsch Apoth Ztg 152, 3880-3, 2012

Wehling M. Chronische Obstipation bei Älteren: Arzneimittel als Fluch und Segen. Verdauungskrankheiten 30, 221-8, 2012

Wehling M. Medikation im Alter. Kognitionseinschränkende Pharmaka. Internist 53, 1240-7, 2012

Wehling M. The wind of change: respecting the past, embracing the future. Arzneimittelforschung 62, 1-2, 2012

Wehling M. Who protects physicians and patients from guidelines? Cardiology 121, 56-8, 2012

Wehling M. Wo stehen Diuretika in der Behandlung der arteriellen Hypertonie heute? Nieren- und Hochdruckkrankheiten 41, 214-24, 2012

Wendler A, Albrecht C, Wehling M. Nongenomic actions of aldosterone and progesterone revisited. Steroids 77, 1002-6, 2012

Wendler A, Wehling M. Translatability scoring in drug development: eight case studies. J Transl Med 10, 39-49, 2012

2011

Buch - Wehling M, Burkhardt H (Hrsg.) Arzneitherapie für Ältere. Springer, Berlin, 2. Auflage, Mai 2011 [ISBN-13: 978-3642173073]

Buchbeitrag - Schmidt B, Wehling M. Wechselwirkungen von Alkohol und Tabak mit Medikamenten. In: Singer M.V., Batra A., Mann K. (Hrsg.) Alkohol und Tabak. Grundlagen und Folgeerkrankungen. Georg Thieme Verlag Stuttgart; 2011, S. 469-79 [ISBN-13: 978-3131466716]

Burkhardt, H., Wehling, M. Probleme bei der Pharmakotherapie älterer Patienten. Urologe 50, 351-62, 2011 (Dieser Beitrag erschien ursprünglich in der Zeitschrift Der Internist 2010;51:737–748)

Davis PJ, Lin HY, Mousa SA, Luidens MK, Hercbergs AA, Wehling M, Davis FB. Overlapping nongenomic and genomic actions of thyroid hormone and steroids. Steroids 76, 829-33, 2011

Feuring M, Wehling M, Ruf A, Burkhardt H, Schultz A. Coagulation status in patients with coronary artery disease taking 100 mg aspirin and healthy volunteers using PFA-100® and ROTEM®. Int J Clin Pharmacol Ther 49, 328-35, 2011

Feuring M, Wehling M, Schultz A. Dalteparin dose-dependently increases ROTEM® thrombelastography parameters only at supratherapeutic anti-factor Xa levels: an in-vitro study. Clin Exp Pharmacol Physiol 38, 783–786, 2011

Feuring M, Wehling M, Schultz A. Lepirudin dose-dependently increases thromboelastography parameters at therapeutic plasma concentrations as measured with ROTEM® - a pilot study. Int J Clin Pharmacol Ther 49, 626-628, 2011

Frohnhofen H, Michalek C, Wehling M. Bewertung von Medikamenten in der Geriatrie mit der neuen FORTA-Klassifikation. Vorläufige klinische Erfahrung. [Assessment of drug treatment in geriatrics with the new FORTA criteria. Preliminary clinical experience] Dtsch Med Wochenschr 136, 1417-1421, 2011

Harenberg J, Krämer R, Giese C, Marx S, Weiss C, Wehling M. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombolysis 32, 267-271, 2011

Harenberg J, Wehling M. Future of anticoagulant therapy. Cardiovasc Ther 29, 291-300, 2011
Schall P, Wehling M. Treatment of arterial hypertension in the very elderly: a meta-analysis of clinical trials. Arzneimittelforschung 61, 221-8, 2011

Schneider HJ, Klotsche J, Wittchen HU, Stalla GK, Schopohl J, Kann PH, Kreitschmann-Andermahr I, Wallaschofski H; German KIMS board and of the DETECT study. Effects of growth hormone replacement within the KIMS survey on estimated cardiovascular risk and predictors of risk reduction in patients with growth hormone deficiency. Clin Endocrinol (Oxf) 75, 825-30, 2011 (as collaborator)

Wehling M. Das Un-Thema “Verschwendung”. Monitor Versorgungsforschung 4 (4), 9, 2011

Wehling M. Drug development in the light of translational science: shine or shade? Drug Discov Today 16, 1076-83, 2011

Wehling M. Guideline-driven polypharmacy in elderly, multimorbid patients is basically flawed: there are almost no guidelines for these patients. J Am Geriatr Soc 59, 376-377, 2011
Wehling M. Mit Blutdrucksenkern kein zusätzliches Risiko eingehen. MediaPlanet Nr. 3/November, S.14, 2011

Wehling M. Wer schützt Ärzte und Patienten vor Leitlinien? [Who protects physicians and patients from guidelines?] Dtsch Med Wochenschr 136, 2560-2561, 2011

Wehling M., Groth H. Challenges of longevity in developed countries: vascular prevention of dementia as an immediate clue to tackle an upcoming medical, social and economic stretch. Neurodegenerative Dis 8, 275-282, 2011

Wendler A, Keller D, Albrecht C, Peluso JJ, Wehling M. Involvement of let-7/miR-98 microRNAs in the regulation of progesterone receptor membrane component 1 expression in ovarian cancer cells. Oncol Rep 25, 273-279, 2011

Wendler A, Wehling M. Is GPR30 the membrane aldosterone receptor postulated 20 years ago? Hypertension 57, e16, 2011

2010

Buch - Wehling M (ed.) Principles of Translational Science in Medicine. From Bench to Bedside. Cambridge University Press, New York, 2010 [ISBN-13: 9780521888691]

Buch - Wehling M, Burkhardt H (Hrsg.) Arzneitherapie für Ältere. Springer, Berlin, 2010 [ISBN-13: 978-3642102141]

Burkhardt H, Wehling M. Probleme bei der Pharmakotherapie älterer Patienten. Internist (Berl) 51, 737–748, 2010

Feuring M, Ruf A, Schultz A, Wehling M. The PFA-100(R) cannot detect blood group-dependent inhibition of platelet function by eptifibatide or abciximab at therapeutic plasma concentrations. Platelets 21, 176-82, 2010

Feuring M, Wehling M, Burkhardt H, Schultz A. Coagulation status in coronary artery disease patients with type II diabetes mellitus compared with non-diabetic coronary artery disease patients using the PFA-100(R) and ROTEM(R). Platelets 21, 616-22, 2010

Harenberg J, Bauersachs R, Diehm C, Lawall H, Burkhardt H, Gerlach H, Darius H, Völler H, Rabe E, Wehling M. Antikoagulation im Alter. [Anticoagulation in the elderly.] Internist (Berl) 51, 1446-1455, 2010

Lösel RM, Schnetzke U, Brinkkoetter PT, Song H, Beck G, Schnuelle P, Höger S, Wehling M, Yard BA. N-octanoyl dopamine, a non-hemodynamic dopamine derivative, for cell protection during hy-pothermic organ preservation. PLoS One 5, e9713, 2010

Wehling M. Antikoagulation bei Hochbetagten: Anpassung an Stoffwechselaktivität und Begleittherapie. Forum Antikoagulation 1, 5 – 8, 2010

Wehling M. Das Geld im Gesundheitswesen reicht noch lange, wenn die Verschwendung aufhört. Teil 2. Monitor-Versorgungsforschung 3, 33-9, 2010

Wehling M. Das Geld im Gesundheitswesen reicht noch lange, wenn die Verschwendung aufhört. Verhaltenstherapie & psychosoziale Praxis (VPP) 42, 129-37, 2010

Wehling M. Multimorbidity and polypharmacy: Which betablocker to use in relation to the pharmacokinetic profile and interaction potential. Arzneimittelforschung 60, 57 – 63, 2010

Wendler A, Baldi E, Harvey B, Nadal A, Norman A, Wehling, M. Position paper: Rapid responses to steroids - current status and future prospects. Eur J Endocrinol 161, 1–7, 2010

Wendler A, Wehling M. The translatability of animal models for clinical development: biomarkers and disease models. Curr Opin Pharmacol 10, 601-6, 2010

Wendler A, Wehling M. Translational research on rapid steroid actions. Steroids 75, 619 – 623, 2010

2009

Feuring M, Wehling M, Ruf A, Schultz A. Circadian variation of platelet function measured with the PFA-100(R). Platelets 20, 466-470, 2009

Sipido KR, Tedgui A, Kristensen SD, Pasterkamp G, Schunkert H, Wehling M, Steg PG, Eisert W, Rademakers F, Casadei B, Fuster V, Cerbai E, Hasenfuss G, Fernandez-Aviles F, Garcia-Dorado D, Vidal M, Hallen M, Dambrauskaite V. Identifying needs and opportunities for advancing translational research in cardiovascular disease. Cardiovasc Res 83, 425-35, 2009

Wehling M, Gladisch R. Arzneimitteltherapie im Alter: erste Erfahrungen aus der gerontopharmakologischen Ambulanz. [Drug therapy in the elderly: initial experiences from an outpatient service in gerontopharmacology] (commentary) Dtsch Med Wochenschr 134, 1121-1123, 2009

Wehling M. Arzneimitteltherapie im Alter: Zu viel und zu wenig, was tun? [Drug therapy in the elderly: too much or too little, what to do?], Reply. Dtsch Med Wochenschr 134, 96, 2009
Wehling M. Assessing the translatability of drug projects: what needs to be scored to predict success? Nature Rev Drug Discov 8, 541-546, 2009

Wehling M. Das Geld im Gesundheitswesen reicht noch lange, wenn die Verschwendung aufhört. Teil 1. Monitor-Versorgungsforschung 2, 46-51, 2009

Wehling M. Die unterschätzte Katastrophe [The underestimated catastrophy (interview by Dr. Jochen Aumiller)] MMW Fortschr Med 151, 16, 2009

Wehling M. Drug development: lost in translation? Arzneimittelforschung 59, 2, 2009

Wehling M. Mehr Sicherheit mit FORTA. Was man alten Patienten verschreiben soll und was nicht (Interview mit Maria Weiss) [More safety with FORTA. What you may prescribe for the elderly and what not (interview by Maria Weiss)] MMW Fortschr Med 151, 17, 2009

Wehling M. Multimorbidity and polypharmacy: how to reduce the harmful drug load and yet add needed drugs in the elderly? Proposal of a new drug classification: fit for the aged. J Am Geriatr Soc 57, 560-561, 2009

Wehling M. Translational medicine: what is it and what could it be? Arzneimittelforschung 59, 3-7, 2009

2008

Brinkkoetter PT, Song H, Losel R, Schnetzke U, Gottmann U, Feng Y, Hanusch C, Beck G, Schnuelle P, Wehling M, van der Woude F, Yard B. Hypothermic injury: the mitochondrial calcium, ATP and ROS love-hate triangle out of balance. Cell Physiol Biochem 22, 195-204, 2008

Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost 34, 39-57, 2008

Lösel RM, Besong D, Peluso JJ, Wehling M. Progesterone receptor membrane component 1-Many tasks for a versatile protein. Steroids 73, 929-934, 2008

Mansouri MR, Schuster J, Badhai J, Stattin EL, Lösel R, Wehling M, Carlsson B, Hovatta O, Karlström PO, Golovleva I, Toniolo D, Bione S, Peluso J, Dahl N. Alterations in the expression, structure and function of progesterone receptor membrane component-1 (PGRMC1) in premature ovarian failure. Hum Mol Genet 17, 3776-3783, 2008

Schwartz JI, Agrawal NG, Wehling M, Musse, BJ, Gumbs CP, Michiels N, De Smet M, Wagner JA. Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib. Br J Clin Pharmacol 66, 811-817, 2008

Silber S, Jarre F, Pittrow D, Klotsche J, Pieper L, Zeiher AM, Wittchen HU; DETECT-Studiengruppe. [Cardiovascular risk assessment by primary-care physicians in Germany and its lack of agreement with the Established Risk Scores (DETECT)] Med Klin (Munich) 103, 638-45, 2008

Weber M, Wehling M, Losel R. Proteins interact with the cytosolic mineralocorticoid receptor depending on the ligand. Am J Physiol Heart Circ Physiol 295, H361-365, 2008

Wehling M. Arzneimitteltherapie im Alter: Zu viel und zu wenig, was tun? [Drug therapy in the elderly: too much or too little, what to do?] (Kommentar) Dtsch Med Wochenschr 133, 2289-2291, 2008
Wehling M. Nachteile durch Statin-Wechsel: Fehleinschätzung? Erste Schäden durch das IQWiG sind messbar. Cardio News 11, 32-33, 2008

Wehling M. Positionierung von Kombinationen aus ACE-Hemmer/Dihydropyridinkalziumantagonisten in der antihypertensiven Therapie: Lercanidipin/Enalapril als Beispiel. Nieren- und Hochdruckkrankheiten 37, 576–585, 2008

Wehling M. Translational medicine: science or wishful thinking? J Transl Med 6, 31, 2008
Wehling M. Translationsforschung – Wege aus der Krise. Dtsch Ärzteblatt 105, A154-A155, 2008

Zhang L, Kanda Y, Roberts DJ, Ecker JL., Losel R, Wehling M, Peluso JJ, Pru JK. Expression of progesterone receptor membrane component 1 and its partner serpine 1 mRNA binding protein in uterine and placental tissues of the mouse and human. Mol Cell Endocrinol 287, 81-89, 2008

2007

Burkhardt H, Wehling M, Gladisch R. Pharmakotherapie älterer Patienten. Internist (Berl) 48, 1220-1231, 2007

Burkhardt H, Wehling M, Gladisch R. Prävention unerwünschter Arzneimittelwirkungen bei älteren Patienten. Z Gerontol Geriatr 40, 241-54, 2007

Roell A, Schueller P, Schultz A, Lösel R, Wehling M, Christ M, Feuring M. Effect of oral contraceptives and ovarian cycle on platelet function. Platelets 18, 165-170, 2007

Wehling M, Schultz A, Lösel R. To be or not to be (a receptor). Steroids 72, 107-110, 2007
Wehling M. Kommentar zur Bewertung des Einsatzes kurzwirksamer Insulinanaloga bei Typ-I-Diabetikern durch das Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Diabetologe 3, 372-379, 2007

Kontextspalte